Navigation Links
Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Vascular Imaging Applications of Its PS-Targeting Platform
Date:6/24/2009

pands the breadth of our intellectual property around our PS-targeting platform," said Steven W. King, president and CEO of Peregrine. "This patent protects expanded use of bavituximab and other PS-targeting antibodies to track disease and treatment status in cancer patients. The growing patent estate around our PS-targeting technology provides us with new options and applications for leveraging our PS-targeting antibodies."

Bavituximab, Peregrine's most advanced PS-targeting antibody, is currently being tested in combination with chemotherapy in one Phase II trial in advanced lung cancer and two Phase II trials in advanced breast cancer. Interim data from these studies has been promising.

U.S. Patent #7,550,141, which was issued on June 23, 2009, was granted to the University of Texas System and is exclusively licensed to Peregrine Pharmaceuticals.

1. M Jennewein, M Lewis, D Zhao, E Tsyganov, N Slavine, J He, L Watkins, V Kodibagkar, S O'Kelly, P Kulkarni, P Antich, A Hermanne, F Rosch, R Mason, P Thorpe, Vascular Imaging of Solid Tumors in Rats with a Radioactive Arsenic-Labeled Antibody that Binds Exposed Phosphatidylserine, Clinical Cancer Research. March 1, 2008.

About Phosphatidylserine (PS)-Targeting Antibodies

The rapid and disorganized growth that is the hallmark of cancer results in the exposure of the lipid phosphatidylserine (PS) on the surface of tumor blood vessels. Since PS typically is not exposed on the surface of normal tissues, it represents a unique target for cancer diagnostics and therapeutics. Bavituximab is a monoclonal antibody that specifically targets PS exposed on the surface of the cells lining tumor blood vessels. It currently is in three Phase II clinical trials for the treatment of advanced breast cancer and advanced lung cancer. Further information on the role of exposed PS in the tumor environment can be found in the Anti
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. ASCO Research Foundation Grant Will Support Study of Peregrines Bavituximab in Lung Cancer
2. Peregrine Pharmaceuticals Reports Progress in Cotara(R) Brain Cancer Clinical Program
3. Peregrine Pharmaceuticals Receives Additional Time to Regain Compliance With NASDAQs Minimum Bid Price Rule
4. Peregrine Pharmaceuticals to Report Third Quarter FY 2009 Financial Results
5. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Breast Cancer Study
6. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009
7. Peregrine Pharmaceuticals Awarded Broad New U.S. Patent for Anti-Viral Applications of Phospholipid-Targeting Antibodies
8. Data Published in Nature Medicine Highlights Ability of Peregrine Pharmaceuticals Bavituximab to Cure Lethal Virus Infections
9. Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials
10. Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
11. Positive Results From Peregrine Pharmaceuticals Bavituximab Phase l HCV Trial Presented at AASLD Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... ... July 31, 2015 , ... The 2015 ALS Ice Bucket Challenge ... and the Boston Red Sox honor Ice Bucket co-founders Pat Quinn and Pete Frates, ... $100,000 to further collaborative efforts among the ALS organizations to find treatments and cures ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated products held at ... to. , Instead of risking containment — or even destruction — of products, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Burnaby ... post that encourages the understanding and treatment of ankle sprains. A common sports ... remedies. This can be dangerous if the condition augments and causes more disruption. ...
(Date:7/31/2015)... ... July 31, 2015 , ... everMaya ( http://evermaya.com/ ), a ... line will be named for Madeline Stuart, an 18-year-old model from Brisbane, Australia. ... model with Down syndrome, gracing the front pages of publications across the world. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Eldermark Software, the innovative leader ... Aging Services Technologies (CAST) Medication Management Technologies whitepaper. The whitepaper is a compilation ... the benefits of using medication management technologies . , Eldermark’s ...
Breaking Medicine News(10 mins):Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 2Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 3Health News:Major League Baseball Joins MDA and Fourteen Other ALS Organizations to Launch ALS Ice Bucket Challenge 2015 4Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Absolute PhysioCare & Sports Rehab Promotes Understanding & Treatment of Ankle Sprains 2Health News:everMaya to Launch Madeline Stuart Handbag Line 2Health News:everMaya to Launch Madeline Stuart Handbag Line 3Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 2Health News:LeadingAge Selects Eldermark Case Study to Highlight Medication Error Reduction Results 3
... 8 Brookdale Senior Living Inc. (NYSE: BKD ... disclosed public offering of 13,953,489 shares of common stock, at ... underwriters in the offering exercised in full their option to ... at the public offering price, resulting in net proceeds to ...
... CITY, June 8 Qqest Software Systems today announced that ... and attendance software, as well as the company,s Payroll Services. ... over 5,000 medical procedures each year. Prior to adopting Qqest,s ... manual time clock and paper time cards to track time. ...
... ("Scient,x" or the "Company") announced today that it has ... Corporation and an incremental equity investment by the Company,s ... equity package amounts to $12.5 million. Terms were ... CEO of Scient,x stated, "I am excited that Scient,x ...
... Year-Long Phase 2 Diabetes Study Results Presented at ADA Annual ... VIVUS, Inc. (Nasdaq: VVUS ), a biopharmaceutical ... obesity, diabetes and sexual health, today announced that data from ... with type 2 diabetes are being highlighted in an oral ...
... expert cautions, , MONDAY, June 8 (HealthDay News) -- New ... might cause their disease to relapse may be reassured by a ... women. , The study, in the June 8 issue of ... with multiple sclerosis (MS) who breast-fed exclusively for two months or ...
... strong among those in their 20s, study finds, , MONDAY, ... colorectal cancer rates in the United States in the past ... on the upswing among people younger than 50. , The ... now running annually at 2.8 percent and 2.2 percent among ...
Cached Medicine News:Health News:Brookdale Announces Completion of Follow-On Offering 2Health News:Brookdale Announces Completion of Follow-On Offering 3Health News:Brookdale Announces Completion of Follow-On Offering 4Health News:Brookdale Announces Completion of Follow-On Offering 5Health News:Colorado Gastroenterology Chooses Qqest's TimeForce, Payroll Services 2Health News:Scient'x Groupe, S.A. Announces Completion of Credit Facility and Incremental Capital Infusion 2Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 2Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 3Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 4Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 5Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 6Health News:VIVUS' Qnexa Shows Significantly Improved Blood Sugar Control Through Weight Loss In Patients With Type 2 Diabetes 7Health News:Breast-feeding OK for Most Moms with MS 2Health News:Breast-feeding OK for Most Moms with MS 3Health News:Colorectal Cancer Rates Rising for Under 50 Set 2Health News:Colorectal Cancer Rates Rising for Under 50 Set 3
(Date:7/31/2015)... HILL, N.C. , July 31, 2015 /PRNewswire/ ... product success in the biopharmaceutical market. Patients are ... process of selecting and switching therapies. This shift ... is pushing marketers, efforts toward patient-focused marketing. ... patient engagement, marketers have learned it,s important to ...
(Date:7/31/2015)...  In today,s ever-changing marketplace, call centers must meet ... connected, and increasingly impatient with slow service. The need ... and tools is driving call centers to explore new ... According to research by benchmarking firm, Best Practices, LLC, ... a call center study realize the impact of social ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed... -- DALLAS, November 10, 2010 ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
... Md., Nov. 9, 2010 Most makers of approved ... and meeting targets for postmarketing studies/clinical trials in a ... the U.S. Food and Drug Administration (FDA). ... http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) The study, based on ...
Cached Medicine Technology:Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 2Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 3Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 4Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 5Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 6Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 7Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 8Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015 9FDA: Majority of Drug and Biological Product Makers Meeting Postmarketing Requirements and Commitments 2
Test for AFP...
Test for AFP...
Enzyme immunoassay for the quantitative determination of ovarian cancer antigen CA125 in human serum...
For in vitro diagnostic use,with the IMMULITE 2000 Analyzer for,the quantitative measurement of prostatic,acid phosphatase (PAP) in serum, as an,aid in patient management....
Medicine Products: